UOH and Krismo Biosciences announce collaboration to develop treatments for inflammatory diseases

The University of Hyderabad (UOH) and Krismo Biosciences Private Limited, a biotech startup incubated at Aspire-Bionest, announced a partnership on Saturday. The purpose of the duo is to develop next-generation therapies for inflammatory diseases and severe infection conditions.

According to the official release, the focus will be on designing antibody-based therapies to effectively combat viral infections, including dengue, Covid-19 and influenza, as well as effective toxins produced by harmful bacteria that lead to harmful bacteria that cause attenuation conditions.

The agreement outlines the common goals of developing novel therapeutics that cover collaborative approaches to preclinical toxicology and non-GLP studies to apply for relevant research grants.

At the signing ceremony of the agreement, Nooruddin Khan of the Department of Animal Biology (UOH) said: “The partnership represents the best of both worlds – outstanding academic and industry innovation – to jointly solve emergency medical challenges.”

Krishna Mohan of Krismo Biosciences said the collaboration will provide patients with practical, affordable and impactful solutions.

The initiative was promoted by the University’s Technology Enablement Centre (UOH-TEC), which was established with the support of the Ministry of Science and Technology, the Government of India.

UOH-TEC Project Coordinator S. Rajagopal highlighted the role of the Centre in encouraging collaboration.

“We are actively encouraging our faculty to translate their valuable knowledge into tangible technologies and products that strictly meet pressing social needs,” he said.

He confirmed TEC's commitment to connecting academic innovators with established industry partners to put innovation at the forefront.